GLP-1 for Type 2 Diabetes in Canada

What glp-1 for type 2 diabetes costs in Canada, which licensed clinics prescribe it, and what the evidence actually supports.

Updated: July 28, 2026

Last reviewed: July 27, 2026 · Editorial team · Canadian availability verified per province

Editorial testing in progress

We have not finished verifying Canadian glp-1 for type 2 diabetes providers against real provincial availability, and we would rather publish nothing than publish rankings we have not checked. In the meantime, our published categories below are live.

GLP-1 Weight Loss Semaglutide

Prescription notice

GLP-1 medications, finasteride, NAD+ injections and the other treatments compared on this site are prescription-only in Canada. A prescription is issued only when a clinician licensed in your province determines it is clinically appropriate for you. Approval is never guaranteed.

Explore More Treatments

Best GLP-1 Weight Loss in Canada

Health Canada-authorized GLP-1 weight loss programs from licensed Canadian telehealth clinics, compared on all-in monthly cost.

Best Semaglutide in Canada

Semaglutide in Canada — generic, Ozempic and Wegovy — from licensed Canadian telehealth clinics, compared on all-in monthly cost.

GLP-1 for Type 2 Diabetes Availability by Province

Telehealth is regulated provincially in Canada. Confirm your province is served before paying a consultation fee.

Ontario British Columbia Alberta Quebec Manitoba Saskatchewan Nova Scotia New Brunswick Prince Edward Island Newfoundland and Labrador

Frequently Asked Questions

More often than for weight management. Several provincial drug benefit programs list semaglutide for type 2 diabetes, frequently with special-authorisation criteria attached, and private plans commonly cover it on the diabetes indication. Check your provincial formulary and your private plan separately — they follow different rules.

Type 2 diabetes needs ongoing bloodwork, foot and eye screening, and coordinated care that a single-medication telehealth program is not designed to deliver. A virtual platform can be part of the picture, but Diabetes Canada guidance assumes a continuing clinical relationship. Do not substitute one for the other.

References and further reading

Diabetes Canada, Pharmacologic Glycemic Management guidelines (Diabetes Canada). How GLP-1 medicines fit into Canadian diabetes care.
NEJM, SELECT cardiovascular outcomes trial (New England Journal of Medicine). Cardiovascular benefit in overweight and obesity.
Canada's Drug Agency (CDA-AMC), semaglutide reimbursement review (Canada's Drug Agency). Reimbursement, coverage, and cost-effectiveness review.

Advertising & Affiliate Disclosure: We may receive compensation when you click on links to partners featured on this site. Our rankings and recommendations are based on our independent research methodology and editorial standards, not on sponsorship or payment. Some links are affiliate links, which means we may earn a commission at no extra cost to you if you make a purchase.

Medical Disclaimer: The content on this site is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for medical questions, treatment decisions, or emergency care. Do not disregard professional medical advice or delay seeking it based on information found here.